The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: A Sarah Cannon Research Institute phase II trial.
J. D. Zubkus
No relevant relationships to disclose
D. B. Daniel
No relevant relationships to disclose
J. F. Eakle
No relevant relationships to disclose
R. G. Bechhold
No relevant relationships to disclose
M. Shastry
No relevant relationships to disclose
P. S. Tucker
No relevant relationships to disclose
H. A. Burris
No relevant relationships to disclose
J. D. Hainsworth
No relevant relationships to disclose
D. A. Yardley
No relevant relationships to disclose